number of access : ?
number of downloads : ?
ID 114195
Author
Kajikawa, Masato Hiroshima University
Maruhashi, Tatsuya Hiroshima University
Hidaka, Takayuki Hiroshima University
Matsui, Shogo Hiroshima University
Hashimoto, Haruki Hiroshima University
Takaeko, Yuji Hiroshima University
Nakano, Yukiko Hiroshima University
Kurisu, Satoshi Hiroshima University
Kihara, Yasuki Hiroshima University
Mohamad Yusoff, Farina Hiroshima University
Kishimoto, Shinji Hiroshima University
Chayama, Kazuaki Hiroshima University
Goto, Chikara Hiroshima International University
Noma, Kensuke Hiroshima University
Nakashima, Ayumu Hiroshima University
Hiro, Takafumi Nihon University
Hirayama, Atsushi Nihon University
Shiina, Kazuki Tokyo Medical University
Tomiyama, Hirofumi Tokyo Medical University
Amano, Rie The University of Tokushima
Higashi, Yukihito Hiroshima University
Content Type
Journal Article
Description
The dipeptidyl peptidase-4 inhibitor saxagliptin is a widely used antihyperglycemic agent in patients with type 2 diabetes. The purpose of this study was to evaluate the effects of saxagliptin on endothelial function in patients with type 2 diabetes. This was a prospective, multicenter, interventional study. A total of 34 patients with type 2 diabetes were enrolled at four university hospitals in Japan. Treatment of patients was initially started with saxagliptin at a dose of 5 mg daily. Assessment of endothelial function assessed by flow-mediated vasodilation (FMD) and measurement of stromal cell-derived factor-1α (SDF-1α) were conducted at baseline and at 3 months after treatment with saxagliptin. A total of 31 patients with type 2 diabetes were included in the analysis. Saxagliptin significantly increased FMD from 3.1 ± 3.1% to 4.2 ± 2.4% (P = 0.032) and significantly decreased total cholesterol from 190 ± 24 mg/dL to 181 ± 25 mg/dL (P = 0.002), glucose from 160 ± 53 mg/dL to 133 ± 25 mg/dL (P < 0.001), HbA1c from 7.5 ± 0.6% to 7.0 ± 0.6% (P < 0.001), urine albumin-to-creatinine ratio from 63.8 ± 134.2 mg/g to 40.9 ± 83.0 mg/g (P = 0.043), and total SDF-1α from 2108 ± 243 pg/mL to 1284 ± 345 pg/mL (P < 0.001). These findings suggest that saxagliptin is effective for improving endothelial function.
Journal Title
Scientific Reports
ISSN
20452322
Publisher
Springer Nature
Volume
9
Start Page
10206
Published Date
2019-07-15
Rights
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences
University Hospital